ScreenerHero

ACXP Acurx Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · acurxpharma.com
1.300USD-0.76%Mkt Cap: 7.23M $P/E: —

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap7.23M USD
Enterprise Value-3.75M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.97M USD
Revenue/Share—
Last Price1.300 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.75
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.75
EPS (TTM)-2.65
EPS (Forward)-1.75
52W Range
1.2301% of range8.340
52W High8.340 USD
52W Low1.230 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.21%
ROA-103.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-47.26%
Net Debt-10.66M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio3.88
Quick Ratio3.80
Book Value/Sh1.74 USD
Cash/Share2.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateAug 5, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.00 USD
Upside (mean)+1207.7%
Target Range10.00 USD – 31.00 USD
10.00+1207.7% to mean31.00
# Analysts3
Ownership
Shares Out.5.56M
Float5.14M
Insiders2.31%
Institutions3.65%
Short Interest
Short Ratio0.8d
Short % Float2.29%
Short % Out.2.23%
Shares Short124.05K
Short (prev mo.)94.13K
Technical
SMA 501.412 (-7.9%)
SMA 2002.153 (-39.6%)
Beta-2.05
S&P 52W Chg16.45%
Avg Vol (30d)130.20K
Avg Vol (10d)99.55K
Technical Indicators
RSI (14)41.4
MACD-0.0414
MACD Signal-0.0415
MACD Hist.+0.0002
BB Upper1.447 USD
BB Middle1.345 USD
BB Lower1.244 USD
BB Width15.15%
ATR (14)0.0677 USD
Vol Ratio (20d)0.87x